LIVIVO - Search results -

Search results

Result 1 - 10 of total 112

Search options

Book ; Online ; E-Book: Sterbehilfe in Belgien

Ricot, Jacques / Dijn, Herman de / Klesse, Raimund / Beuselinck, Benoit / Blanchard, Julie / Dopchie, Catherine / Frings, Marie / Haekens, An / Karplus, Rivka / Devos, Timothy

Erfahrungen, Reflexionen, Einsichten

(Forum Psychosozial)

2022

Author's details	Timothy Devos (Hg.); aus dem Französischen von Jürgen Schröder ; mit einem Vorwort zur deutschen Ausgabe von Raimund Klesse ; mit Vorworten von Jaques Ricot und Herman de Dijn und einem Nachwort von Timothy Devos ; mit Beiträgen von Benoit Beuselinck, Julie Blanchadr, Catherine Dopchie, Marie Frings, An Haekens, Rivka Karplus, Willlem Lemmens, Francois Trufin und eric Vermeer
Series title	Forum Psychosozial
Keywords	Electronic books
Language	German
Size	1 Online-Ressource (187 Seiten), Illustrationen
Edition	Deutsche Erstausgabe
Publisher	Psychosozial Verlag
Publishing place	Gießen
Publishing country	Germany
Document type	Book ; Online ; E-Book
Note	Description based on publisher supplied metadata and other sources
Remark	Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
HBZ-ID	HT021707411
ISBN	978-3-8379-7893-3 ; 9783837931655 ; 3-8379-7893-1 ; 383793165X
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Systemic autoimmune rheumatic diseases as paraneoplastic phenomena: 3 illustrative case reports and narrative review of the literature.

Poelman, Anouck / Neerinckx, Barbara / Beuselinck, Benoit / De Langhe, Ellen

Acta clinica Belgica

2023 Volume 78, Issue 5, Page(s) 410–417

Abstract: Objectives: Systemic autoimmune rheumatic diseases can occur as paraneoplastic phenomena in the context of underlying malignancies. We present three illustrative clinical cases and a narrative literature review focusing on systemic sclerosis, ... ...

Abstract	Objectives: Systemic autoimmune rheumatic diseases can occur as paraneoplastic phenomena in the context of underlying malignancies. We present three illustrative clinical cases and a narrative literature review focusing on systemic sclerosis, dermatomyositis and palmar fasciitis and polyarthritis syndrome. Methods: Medical data of three patients from the University Hospitals Leuven were retrospectively and anonymously obtained and reviewed. A narrative review was performed, searching the databases of PubMed, Embase and Cochrane Library. Results: Systemic sclerosis, dermatomyositis and palmar fasciitis and polyarthritis syndrome are systemic autoimmune rheumatic diseases that can present as paraneoplastic phenomena. Systemic autoimmune rheumatic diseases are often associated with the presence of specific autoantibodies, some associated with a high likelihood of underlying malignancy. The presence of anti-ribonucleic acid polymerase III antibodies and anti-transcription intermediary factor 1 gamma antibodies indicates an increased risk of underlying cancer in systemic sclerosis and dermatomyositis, respectively. Individual patient prognosis can be improved through early detection of underlying malignancy, hence the importance of adequate cancer screening. Conclusion: Some systemic autoimmune rheumatic diseases can appear as paraneoplastic phenomena, whereby the presence of specific autoantibodies is known to be related to the likelihood of underlying malignancy. We highlight the importance of clinician's knowledge of these distinct features, as it facilitates early detection and treatment of underlying malignancy, thereby improving individual patient prognosis.
MeSH term(s)	Humans ; Rheumatic Diseases/complications ; Dermatomyositis/complications ; Paraneoplastic Syndromes/etiology ; Paraneoplastic Syndromes/complications ; Retrospective Studies ; Fasciitis/complications ; Autoantibodies ; Neoplasms/complications ; Arthritis/complications ; Scleroderma, Systemic/complications ; Scleroderma, Systemic/diagnosis ; Autoimmune Diseases/complications ; Autoimmune Diseases/diagnosis
Chemical Substances	Autoantibodies
Language	English
Publishing date	2023-02-27
Publishing country	England
Document type	Review ; Case Reports ; Journal Article
ZDB-ID	390201-8
ISSN	2295-3337 ; 0001-5512 ; 1784-3286
ISSN (online)	2295-3337
ISSN	0001-5512 ; 1784-3286
DOI	10.1080/17843286.2023.2183577
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.283: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Tailoring treatment in metastatic renal cell carcinoma.

Roussel, Eduard / Beuselinck, Benoit / Albersen, Maarten

Nature reviews. Urology

2022 Volume 19, Issue 8, Page(s) 455–456

MeSH term(s)	Carcinoma, Renal Cell/pathology ; Humans ; Kidney Neoplasms/pathology ; Kidney Neoplasms/therapy ; Retrospective Studies
Language	English
Publishing date	2022-06-09
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	2493737-X
ISSN	1759-4820 ; 1759-4812
ISSN (online)	1759-4820
ISSN	1759-4812
DOI	10.1038/s41585-022-00615-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6030: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Equivocal evaluation of progressive disease in patients treated with immune checkpoint inhibitors: a challenge for clinical trials and biomarker research.

Kyriazoglou, Anastasios / Beuselinck, Benoit

Acta clinica Belgica

2020 Volume 77, Issue 2, Page(s) 406–409

Abstract: We present two patient cases (one with bladder carcinoma and one with renal cell carcinoma) who consulted our department of General Medical Oncology, after having been treated in other hospitals in two clinical trials with immune checkpoint inhibitors ... ...

Abstract	We present two patient cases (one with bladder carcinoma and one with renal cell carcinoma) who consulted our department of General Medical Oncology, after having been treated in other hospitals in two clinical trials with immune checkpoint inhibitors and having been dismissed from the trials after 5 months of therapy for progressive disease. They consulted to discuss consecutive treatment opportunities. However, longer follow-up has shown that both patients were dismissed equivocally from both trials. We are worried that equivocal response evaluation in the context of clinical trials with immune checkpoint inhibitors, due to pseudo-progression or delayed responses, can negatively impact trial outcomes as well as biomarker research.
MeSH term(s)	Biomarkers ; Carcinoma, Renal Cell/drug therapy ; Humans ; Immune Checkpoint Inhibitors ; Kidney Neoplasms/drug therapy ; Urinary Bladder Neoplasms/drug therapy
Chemical Substances	Biomarkers ; Immune Checkpoint Inhibitors
Language	English
Publishing date	2020-12-11
Publishing country	England
Document type	Journal Article
ZDB-ID	390201-8
ISSN	2295-3337 ; 0001-5512 ; 1784-3286
ISSN (online)	2295-3337
ISSN	0001-5512 ; 1784-3286
DOI	10.1080/17843286.2020.1853886
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.283: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma.

Brackenier, Cedric / Kinget, Lisa / Cappuyns, Sarah / Verslype, Chris / Beuselinck, Benoit / Dekervel, Jeroen

Cancers

2023 Volume 15, Issue 2

Abstract: Tyrosine kinase inhibitors (TKIs) with antiangiogenic properties, such as sorafenib, have been the standard choice to systemically treat hepatocellular carcinoma for over a decade. More recently, encouraging results were obtained using immune checkpoint ... ...

Abstract	Tyrosine kinase inhibitors (TKIs) with antiangiogenic properties, such as sorafenib, have been the standard choice to systemically treat hepatocellular carcinoma for over a decade. More recently, encouraging results were obtained using immune checkpoint inhibitors, although head-to-head comparisons with sorafenib in phase 3 trials could not demonstrate superiority in terms of overall survival. The IMbrave150 was a breakthrough study that resulted in atezolizumab/bevacizumab, a combination of an antiangiogenic and an immune checkpoint inhibitor, as a new standard of care for advanced HCC. This review discusses the mode of action, clinical efficacy, and biomarker research for both drug classes and for the combination therapy. Moreover, the synergy between atezolizumab and bevacizumab is highlighted, unraveling pathophysiological mechanisms underlying an enhanced anticancer immunity by changing the immunosuppressed to a more immunoreactive tumor microenvironment (TME). This is achieved by upregulation of antigen presentation, upregulation of T-cell proliferation, trafficking and infiltration, impairing recruitment, and proliferation of immunosuppressive cells in the TME. However, more insights are needed to identify biomarkers of response that may improve patient selection and outcome.
Language	English
Publishing date	2023-01-05
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15020348
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Three Years After CARMENA: What Have We Learned?

Roussel, Eduard / Beuselinck, Benoit / Albersen, Maarten

European urology

2021 Volume 80, Issue 4, Page(s) 425–427

Abstract: Cytoreductive nephrectomy makes way for more effective systemic treatments in the current mRCC treatment paradigm, as disease volume and the number of IMDC risk factors increase. Careful patient selection for upfront or deferred cytoreductive nephrectomy ...

Abstract	Cytoreductive nephrectomy makes way for more effective systemic treatments in the current mRCC treatment paradigm, as disease volume and the number of IMDC risk factors increase. Careful patient selection for upfront or deferred cytoreductive nephrectomy based on these criteria remains key.
MeSH term(s)	Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/surgery ; Cytoreduction Surgical Procedures ; Humans ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/surgery ; Nephrectomy ; Treatment Outcome
Language	English
Publishing date	2021-07-27
Publishing country	Switzerland
Document type	Editorial ; Comment
ZDB-ID	193790-x
ISSN	1873-7560 ; 1421-993X ; 0302-2838
ISSN (online)	1873-7560 ; 1421-993X
ISSN	0302-2838
DOI	10.1016/j.eururo.2021.07.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1247: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 294: Show issues

Order via subito

Details ▾

Article ; Online: Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients.

Coropciuc, Ruxandra / Coopman, Renaat / Garip, Melisa / Gielen, Evelien / Politis, Constantinus / Van den Wyngaert, Tim / Beuselinck, Benoit

Bone

2023 Volume 170, Page(s) 116722

Abstract: This study investigated the incidence, risk factors, and outcome of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents for osteoporosis or bone metastases. 240 patients with a median drug ... ...

Abstract	This study investigated the incidence, risk factors, and outcome of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents for osteoporosis or bone metastases. 240 patients with a median drug exposure of 43 months were retrospectively studied. The incidence of MRONJ after dental extraction in the osteoporosis cohort was 2.7 % per person-year (95 % CI 1.6-4.6 %) (n = 13/126), and for the bone metastases cohort 26.4 % per person-year (95 % CI 20.4-34.2 %) (n = 58/114). 92 % of MRONJ cases were stage 1. Dental infection as the reason for extraction increased the osteonecrosis risk in the osteoporosis (OR 22.77; 95 % CI 2.85-181.62; p = 0.003) and bone metastases cohorts (OR 2.72; 95 % CI 1.28-5.81; p = 0.010). Using leukocyte and platelet-rich fibrin reduced this risk by 84 % (p = 0.003), as did antibiotics use by 86-93 % (p = 0.013). Within the bone metastases cohort, an interval since last administration of at least 3 months reduced risk of MRONJ (OR 0.83; 95 % CI 0.72-0.97; p = 0.018). Mucosal healing occurred in 11/13 patients (84.6 %; 95 % CI 54.5-98.1 %) with osteoporosis and 31/58 patients (53.4 %; 95 % CI 40.0-66.7 %) with bone metastases. In conclusion, though the MRONJ risk in this selected population taking antiresorptive agents and presenting to the Oral Maxillofacial Surgery clinic for a dental extraction is considerable and higher in those with dental infections, preventive measures such as antibiotics and use of LRPF membranes may significantly reduce that risk.
MeSH term(s)	Humans ; Bone Density Conservation Agents/adverse effects ; Retrospective Studies ; Bisphosphonate-Associated Osteonecrosis of the Jaw/prevention & control ; Osteoporosis/chemically induced ; Bone Neoplasms/secondary ; Anti-Bacterial Agents ; Tooth Extraction/adverse effects ; Diphosphonates/adverse effects
Chemical Substances	Bone Density Conservation Agents ; Anti-Bacterial Agents ; Diphosphonates
Language	English
Publishing date	2023-02-28
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	632515-4
ISSN	1873-2763 ; 8756-3282
ISSN (online)	1873-2763
ISSN	8756-3282
DOI	10.1016/j.bone.2023.116722
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1571: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 332: Show issues

Order via subito

Details ▾

Article ; Online: Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis.

Haaker, Lorenz / Baldewijns, Marcella / De Wever, Liesbeth / Albersen, Maarten / Debruyne, Philip R / Wynendaele, Wim / De Meerleer, Gert / Beuselinck, Benoit

Clinical genitourinary cancer

2023 Volume 21, Issue 4, Page(s) 442–451

Abstract: Introduction: Immune checkpoint inhibitors (ICI) are part of the current standard of care for metastatic clear-cell renal cell carcinoma (m-ccRCC). ICI can elicit diverse tumor response, including atypical responses such as pseudoprogression (psPD), ... ...

Abstract	Introduction: Immune checkpoint inhibitors (ICI) are part of the current standard of care for metastatic clear-cell renal cell carcinoma (m-ccRCC). ICI can elicit diverse tumor response, including atypical responses such as pseudoprogression (psPD), mixed responses (MR) and late responses. We aimed to analyze the occurrence and prognostic impact of atypical responses in m-ccRCC patients treated with nivolumab. Materials and methods: A retrospective analysis of m-ccRCC patients treated with nivolumab in first or subsequent therapy line between November 2012 and July 2022 was performed. All radiographic evaluations of eligible patients were analyzed using the iRECIST consensus guideline. Results: We assessed 247 baseline target lesions in 94 eligible patients. MR occurred in 11 (11.7%) patients: in 7 at first CT (computed tomography) evaluation (CT1) and in 4 at second CT evaluation (CT2). In 8 patients (73%), MR evolved to confirmed PD. In 3 patients (27%), MR evolved towards a partial response (PR) and was thus a psPD. psPD occurred in 8 (8.5%) patients: with psPD features at CT1 in 3 patients, with psPD features at CT2 in 2 patients, and with MR features at CT1 in 3 patients. psPD patients had similar progression-free survival and overall survival compared to patients displaying PR as best response without a phase of psPD. 76 patients were treated beyond immune unconfirmed progressive disease (iUPD) at any moment: 12 (16%) of them evolved towards PR or stable disease (SD). Treatment beyond immune confirmed PD (iCPD) in 20 patients did not lead to PR or SD. Conclusion: Atypical responses such as psPD and MR occurred in 8.5% and 11.7% of m-ccRCC patients treated with nivolumab at CT1 and CT2. Patients with psPD had favorable outcomes, while MR most often evolved to progression. Treatment with nivolumab beyond iCPD did not lead to tumor stabilization or regression.
MeSH term(s)	Humans ; Nivolumab/therapeutic use ; Carcinoma, Renal Cell/diagnostic imaging ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Retrospective Studies ; Kidney Neoplasms/diagnostic imaging ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology ; Disease Progression
Chemical Substances	Nivolumab (31YO63LBSN)
Language	English
Publishing date	2023-03-09
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2225121-2
ISSN	1938-0682 ; 1558-7673
ISSN (online)	1938-0682
ISSN	1558-7673
DOI	10.1016/j.clgc.2023.03.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma.

Roussel, Eduard / Kinget, Lisa / Verbiest, Annelies / Zucman-Rossi, Jessica / Boeckx, Bram / Joniau, Steven / Lambrechts, Diether / Albersen, Maarten / Beuselinck, Benoit

European urology open science

2022 Volume 40, Page(s) 54–57

Abstract: Highly effective systemic treatments have globally improved outcomes in metastatic clear-cell renal cell carcinoma (m-ccRCC). However, despite many efforts, reliable biomarkers predicting individual responses are currently lacking. Moreover, mixed ... ...

Abstract	Highly effective systemic treatments have globally improved outcomes in metastatic clear-cell renal cell carcinoma (m-ccRCC). However, despite many efforts, reliable biomarkers predicting individual responses are currently lacking. Moreover, mixed responses are commonly observed. We hypothesized that molecular heterogeneity between primary tumors and their metastases could flaw biomarker research based on features of the primary tumor and explain mixed responses. Therefore, we studied the heterogeneity of the ccrcc1-4 molecular subtypes across patient-matched primary and metastatic lesions over time in 62 patients with m-ccRCC who underwent both nephrectomy and metastasectomy. These subtypes characterize underlying disease biology and are associated with outcomes in both the primary and metastatic settings. We observed a concordance rate of 58% (95% confidence interval 45-71%). This concordance was not affected by the interval between nephrectomy and resection of the metastatic lesion. Across discordant pairs, the metastatic lesions mostly exhibited a less favorable molecular subtype. Moreover, primary tumors with the favorable ccrcc2 molecular subtype were characterized by favorable prognosis and a long interval between nephrectomy and metastasectomy. Conversely, tumors with the unfavorable ccrcc4 molecular subtype relapsed quickly and had poor prognosis. Thus, the considerable molecular heterogeneity between patient-matched m-ccRCC primary and metastatic lesions provides an explanation for mixed responses to systemic therapy and could impact the development of biomarker studies in which the primary tumor is often considered a surrogate for metastatic disease. Patient summary: We studied primary tumors and metastases from patients with kidney cancer and found considerable heterogeneity in their molecular features. This heterogeneity explains mixed responses to systemic therapy and is important to take into account in future biomarker studies for this disease.
Language	English
Publishing date	2022-05-02
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	3040546-4
ISSN	2666-1683 ; 2058-4881
ISSN (online)	2666-1683
ISSN	2058-4881
DOI	10.1016/j.euros.2022.04.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?

Beuselinck, Benoit / Zucman-Rossi, Jessica

Nature reviews. Urology

2015 Volume 12, Issue 8, Page(s) 424–426

MeSH term(s)	Antineoplastic Agents/therapeutic use ; Carcinoma, Renal Cell/drug therapy ; Cytochrome P-450 CYP3A/genetics ; Female ; Humans ; Indoles/therapeutic use ; Kidney Neoplasms/drug therapy ; Male ; Polymorphism, Single Nucleotide ; Protein Kinase Inhibitors/therapeutic use ; Pyrroles/therapeutic use
Chemical Substances	Antineoplastic Agents ; Indoles ; Protein Kinase Inhibitors ; Pyrroles ; Cytochrome P-450 CYP3A (EC 1.14.14.1)
Language	English
Publishing date	2015-08
Publishing country	England
Document type	Comment ; Journal Article
ZDB-ID	2493737-X
ISSN	1759-4820 ; 1759-4812
ISSN (online)	1759-4820
ISSN	1759-4812
DOI	10.1038/nrurol.2015.149
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6030: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Your last searches

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito